The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain
tricyclic compounds (referred to herein as TC compounds), and especially certain 9H-pyrimido[4,5-b]indole, 9H-pyrido[4′,3′:4,5]pyrrolo[2,3-d]
pyridine, and 9H-1,3,6,9-tetraaza-
fluorene compounds, which, inter alia, inhibit Checkpoint
Kinase 1 (CHK1)
kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both
in vitro and
in vivo, to inhibit CHK1
kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1
kinase function, etc., including proliferative conditions such as
cancer, etc., optionally in combination with another agent, for example, (a)
a DNA topoisomerase I or II inhibitor; (b)
a DNA damaging agent; (c) an
antimetabolite or TS inhibitor; (d) a
microtubule targeted agent; and (e) ionising
radiation.